According to the deal, BeiGene will in-license intetumumab (CNTO-95) for clinical development and commercialization within Australia, China, Hong Kong, New Zealand, Korea, Singapore and Taiwan.
Intetumumab is a fully humanized monoclonal antibody against av integrins that binds to human integrins, helping disruption of tumor cell growth, development and metastases.
BeiGene will also in-license MTKi-327 and retain global rights for development and commercialization for human pharmaceutical uses.
MTKi-327 is a macrocyclic multi-targeted kinase inhibitor of many critical cancer signaling pathways.